Gyros AB licenses patented technology to Cellectricon AB.


Gyros AB today announced finalization of a licensing agreement with Cellectricon AB relating to a patent held by Gyros and applied in major biotech markets worldwide.

Maris Hartmanis, President and CEO at Gyros AB explained “This is the second in a number of licensing agreements that we are pursuing. The patent held by Gyros is very wide ranging and covers the manufacture and use of elastomeric microfluidic devices.”

Jakob Lindberg CEO at Cellectricon added, “Processes covered by the Gyros patent are used within the development of the Dynaflow™ Platform, our first product line. The Dynaflow™ Microchip is a ground-breaking higher-throughput tool offering productivity increase in the drug discovery process, and is already adopted by major pharma. The Gyros patent will in conjunction with Cellectricon’s extensive patent portfolio give us unique possibilities to develop functional cell-based platforms for pharmaceutical companies.”

Gyros and Cellectricon are examples of the unique expertise that exists in the Swedish scientific community for the development and application of microfluidic-based technologies. “Licensing agreements of this sort serve to strengthen both partners and ensure that novel application ideas have a good chance to enter the drug discovery market.” added Mr. Hartmanis.

Gyros recently announced a similar licensing agreement, based on the same patent, with Fluidigm Corporation, a microfluidic company based in California.

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.